SAN DIEGO, March 6, 2018 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces
that President and CEO Michael W.
Nall is scheduled to present a corporate overview at the
30th Annual ROTH Conference on Tuesday, March 13, 2018, at 7:30 a.m. Pacific time (10:30 a.m. Eastern time). The conference is being
held at The Ritz Carlton Laguna Niguel hotel in Dana Point, Calif.
A live webcast of the corporate presentation will be available
on the Company's website at ir.biocept.com. A replay of the
presentation will be available for 90 days.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-30th-annual-roth-conference-300605754.html
SOURCE Biocept, Inc.